Zervas, K <br/><br/>
Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil): a phase II multicenter study.  [electronic resource] 

 -  Annals of oncology : official journal of the European Society for Medical Oncology  Jan 2004 
 - 134-8 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study 
<br/><br/><label>ISSN: </label>0923-7534 
<br/><br/><label>Standard No.: </label>10.1093/annonc/mdh026  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Ambulatory Care<br/>Antineoplastic Combined Chemotherapy Protocols--administration & dosage<br/>Dexamethasone--administration & dosage<br/>Doxorubicin--administration & dosage<br/>Drug Administration Schedule<br/>Female<br/>Humans<br/>Injections, Intravenous<br/>Male<br/>Middle Aged<br/>Multiple Myeloma--drug therapy<br/>Stem Cell Transplantation<br/>Thalidomide--administration & dosage<br/>Transplantation, Autologous<br/>Treatment Outcome<br/>Vincristine--administration & dosage